Activating mutations in the KRAS oncogene are a hallmark of pancreatic ductal adenocarcinoma (PDAC). While pharmacologic targeting of KRAS is very challenging, work from the Lewis lab and others demonstrates that targeting key downstream factors may be a viable strategy. Current work is focused on developing combination treatment strategies that include inhibition of critical downstream protein kinases.